Zhejiang Shengda Bio-Pharm Co., Ltd. Stock

Equities

603079

CNE100002W43

Food Processing

End-of-day quote Shanghai S.E. 06:00:00 2024-05-07 pm EDT 5-day change 1st Jan Change
13.96 CNY -0.43% Intraday chart for Zhejiang Shengda Bio-Pharm Co., Ltd. +8.47% -4.19%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2022 738M 102M Sales 2023 727M 101M Capitalization 2.49B 344M
Net income 2022 31M 4.29M Net income 2023 -54M -7.47M EV / Sales 2022 2.52 x
Net cash position 2022 288M 39.87M Net cash position 2023 88.29M 12.22M EV / Sales 2023 3.3 x
P/E ratio 2022
69.7 x
P/E ratio 2023
-45.5 x
Employees 1,152
Yield 2022
0.48%
Yield 2023
-
Free-Float 41.83%
More Fundamentals * Assessed data
Dynamic Chart
Zhejiang Shengda Bio-Pharm Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Zhejiang Shengda Bio-Pharm Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on Zhejiang Shengda Bio-Pharm Co., Ltd.'s Equity Buyback Plan announced on May 9, 2023. CI
China stocks rise as strength in banks offsets developers' falls RE
Tranche Update on Zhejiang Shengda Bio-Pharm Co., Ltd.'s Equity Buyback Plan announced on May 9, 2023. CI
Zhejiang Shengda Bio-Pharm Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tranche Update on Zhejiang Shengda Bio-Pharm Co., Ltd.'s Equity Buyback Plan announced on May 9, 2023. CI
Zhejiang Shengda Bio-Pharm Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tranche Update on Zhejiang Shengda Bio-Pharm Co., Ltd.'s Equity Buyback Plan announced on May 9, 2023. CI
Zhejiang Shengda Bio-Pharm Co., Ltd. announces an Equity Buyback for CNY 34 million worth of its shares. CI
Zhejiang Shengda Bio-Pharm Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zhejiang Shengda Bio-Pharm Co., Ltd. authorizes a Buyback Plan. CI
Zhejiang Shengda Bio-Pharm Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Zhejiang Shengda Bio-Pharm Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Zhejiang Shengda Bio-Pharm Co., Ltd. announced that it expects to receive CNY 500 million in funding CI
More news
1 day-0.43%
1 week+8.47%
Current month+8.47%
1 month+32.32%
3 months+72.77%
6 months+0.22%
Current year-4.19%
More quotes
1 week
13.00
Extreme 13
14.86
1 month
8.70
Extreme 8.7
14.86
Current year
7.01
Extreme 7.01
15.51
1 year
7.01
Extreme 7.01
16.24
3 years
7.01
Extreme 7.01
20.00
5 years
7.01
Extreme 7.01
43.91
10 years
7.01
Extreme 7.01
43.91
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 13-12-12
Director of Finance/CFO 44 22-04-26
Director/Board Member 38 11-12-31
Members of the board TitleAgeSince
Director/Board Member 59 19-12-17
Director/Board Member 62 21-09-16
Chairman 61 99-02-07
More insiders
Date Price Change Volume
24-05-08 13.96 -0.43% 22,254,850
24-05-07 14.02 -0.99% 28,124,960
24-05-06 14.16 +10.02% 25,183,650
24-04-30 12.87 +10.00% 15,855,780

End-of-day quote Shanghai S.E., May 07, 2024

More quotes
ZHEJIANG SHENGDA BIO-PHARM CO., LTD. is a China-based company principally engaged in the research, development, production and sales of vitamins and biological preservatives. Its vitamin products mainly include biotin and folic acid. Its biological preservative products mainly include natamycin and nisin. The Company distributes its products in domestic market and to overseas markets.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 603079 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW